share_log

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $6

Benzinga ·  May 19, 2023 07:55

Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $5 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment